Neurobiology of α-synuclein

Abstractα-Synuclein is an abundant neuronal protein that has been linked both to normal synaptic function and to neurodegeneration. Most significantly, mutations in the gene encoding for α-synuclein are responsible for Parkinson’s disease (PD) in rare familial cases, and the aggregated protein is a major component of Lewy bodies found in sporadic PD. Here we review recent data regarding the structure, the regulation at the transcriptional and posttranslational level, and the physiologic and aberrant functions of α-synuclein. We focus in particular on the fibrilization potential of α-synuclein and on its link with defects in protein degradation.

[1]  L. Petrucelli,et al.  α-Synuclein Shares Physical and Functional Homology with 14-3-3 Proteins , 1999, The Journal of Neuroscience.

[2]  B. Giasson,et al.  Effects of Oxidative and Nitrative Challenges on α-Synuclein Fibrillogenesis Involve Distinct Mechanisms of Protein Modifications* , 2003, Journal of Biological Chemistry.

[3]  J. Mikkelsen,et al.  Developmental expression of alpha-synuclein in rat hippocampus and cerebral cortex. , 1999, Neuroscience.

[4]  J. Trojanowski,et al.  Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons , 2000, The Journal of Neuroscience.

[5]  Richard Paylor,et al.  Synaptic Vesicle Depletion Correlates with Attenuated Synaptic Responses to Prolonged Repetitive Stimulation in Mice Lacking α-Synuclein , 2002, The Journal of Neuroscience.

[6]  J. Trojanowski,et al.  Induction of alpha-synuclein aggregation by intracellular nitrative insult. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  Peter T Lansbury,et al.  Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. , 2003, Biochemistry.

[8]  L. Stefanis,et al.  Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons. , 2003, Journal of neurochemistry.

[9]  Seung-Jae Lee,et al.  Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. , 2002, The Journal of biological chemistry.

[10]  Sarah J. Tabrizi,et al.  Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .

[11]  P. Worley,et al.  Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. , 1999, Nature genetics.

[12]  J. Schaack,et al.  Overexpression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture , 2002, Brain Research.

[13]  P. S. St George-Hyslop,et al.  alpha-Synuclein membrane interactions and lipid specificity. , 2000, The Journal of biological chemistry.

[14]  R. Perrin,et al.  Exposure to Long Chain Polyunsaturated Fatty Acids Triggers Rapid Multimerization of Synucleins* , 2001, The Journal of Biological Chemistry.

[15]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[16]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[17]  P. Auluck,et al.  Pharmacological prevention of Parkinson disease in Drosophila , 2002, Nature Medicine.

[18]  Tsutomu Hashikawa,et al.  Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. , 2003, Human molecular genetics.

[19]  J. Trojanowski,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[20]  T. Iwatsubo,et al.  Biochemical characterization of the core structure of alpha-synuclein filaments. , 2002, The Journal of biological chemistry.

[21]  P. S. St George-Hyslop,et al.  α-Synuclein Membrane Interactions and Lipid Specificity* , 2000, The Journal of Biological Chemistry.

[22]  V. Uversky,et al.  Pesticides directly accelerate the rate of α‐synuclein fibril formation: a possible factor in Parkinson's disease , 2001, FEBS letters.

[23]  Virginia M. Y. Lee,et al.  Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease , 2001, Journal of neurochemistry.

[24]  P Choi,et al.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[25]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[26]  L. Meijer,et al.  Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. , 2000, The Journal of biological chemistry.

[27]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[28]  A. Brunati,et al.  Multiple phosphorylation of α‐synuclein by protein tyrosine kinase Syk prevents eosin‐induced aggregation , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  M. Farrer,et al.  Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. , 2000, Journal of neurochemistry.

[30]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[31]  Shigenobu Nakamura,et al.  Tyrosine 125 of α-synuclein plays a critical role for dimerization following nitrative stress , 2002, Brain Research.

[32]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[33]  D. Hernandez,et al.  alpha-Synuclein gene haplotypes are associated with Parkinson's disease. , 2001, Human molecular genetics.

[34]  L. Greene,et al.  Release, storage and uptake of catecholamines by a clonal cell line of nerve growth factor (NGF) responsive pheochromocytoma cells , 1977, Brain Research.

[35]  Matthew J. Farrer,et al.  α-synuclein gene haplotypes are associated with Parkinson’s disease , 2001 .

[36]  K. Chung,et al.  Evidence that alpha-synuclein functions as a negative regulator of Ca(++)-dependent alpha-granule release from human platelets. , 2002, Blood.

[37]  L. Meijer,et al.  Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein* , 2000, The Journal of Biological Chemistry.

[38]  R. Blakely,et al.  Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α‐synuclein , 2003, Journal of neurochemistry.

[39]  E. Masliah,et al.  α-Synuclein Protects against Oxidative Stress via Inactivation of the c-Jun N-terminal Kinase Stress-signaling Pathway in Neuronal Cells* , 2002, The Journal of Biological Chemistry.

[40]  MoonHee Lee,et al.  Effect of the overexpression of wild‐type or mutant α‐synuclein on cell susceptibility to insult , 2001 .

[41]  G. Withers,et al.  Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. , 1997, Brain research. Developmental brain research.

[42]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[43]  L. Greene,et al.  Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death , 2001, The Journal of Neuroscience.

[44]  P. Lansbury,et al.  The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.

[45]  T. Iwatsubo,et al.  Biochemical Characterization of the Core Structure of α-Synuclein Filaments* , 2002, The Journal of Biological Chemistry.

[46]  L. Stefanis,et al.  Regulation of α‐synuclein by bFGF in cultured ventral midbrain dopaminergic neurons , 2003 .

[47]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[48]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[49]  R. Krüger,et al.  Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. , 2003, Brain : a journal of neurology.

[50]  P. Worley,et al.  Synphilin-1 associates with α-synuclein and promotes the formation of cytosolic inclusions , 1999, Nature Genetics.

[51]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[52]  Akihiko Iwai,et al.  The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.

[53]  D. Sulzer,et al.  Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.

[54]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[55]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[56]  Philippe Hantraye,et al.  MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.

[57]  A. Graybiel,et al.  A measure of striatal function predicts motor stereotypy , 2000, Nature Neuroscience.

[58]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[59]  David F. Clayton,et al.  Characterization of a novel protein regulated during the critical period for song learning in the zebra finch , 1995, Neuron.

[60]  J. Trojanowski,et al.  Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. , 2001, Experimental neurology.

[61]  B. Giasson,et al.  Chaperone‐like activity of synucleins , 2000, FEBS letters.

[62]  Z. Wszolek,et al.  Reduced expression of the G209A α‐synuclein allele in familial parkinsonism , 1999 .

[63]  L. Thal,et al.  Expression Pattern of Synucleins (Non‐Aβ Component of Alzheimer's Disease Amyloid Precursor Protein/α‐Synuclein) During Murine Brain Development , 1998 .

[64]  Chul-hak Yang,et al.  Structural and functional implications of C-terminal regions of alpha-synuclein. , 2002, Biochemistry.

[65]  P. S. St George-Hyslop,et al.  Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. , 2002, Journal of molecular biology.

[66]  David F. Clayton,et al.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease , 1998, Trends in Neurosciences.

[67]  M. Farrer,et al.  Lack of Nigral Pathology in Transgenic Mice Expressing Human α-Synuclein Driven by the Tyrosine Hydroxylase Promoter , 2001, Neurobiology of Disease.

[68]  J. Trojanowski,et al.  Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. , 2002, Science.

[69]  R. Nussbaum,et al.  α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases* , 2001, The Journal of Biological Chemistry.

[70]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[72]  J. Trojanowski,et al.  Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. , 2003, Journal of neurochemistry.

[73]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[75]  John Q. Trojanowski,et al.  Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult , 2001, The Journal of Neuroscience.

[76]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[77]  I. Kanazawa,et al.  α‐Synuclein forms a complex with transcription factor Elk‐1 , 2001, Journal of neurochemistry.

[78]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[79]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[80]  A. Sidhu,et al.  Attenuation of dopamine transporter activity by alpha-synuclein. , 2003, Neuroscience letters.

[81]  Chul-hak Yang,et al.  Structural and Functional Implications of C-Terminal Regions of α-Synuclein† , 2002 .

[82]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[83]  R. Krüger,et al.  Haploinsufficiency at the α‐synuclein gene underlies phenotypic severity in familial Parkinson’s disease , 2003 .

[84]  A. Manning-Boğ,et al.  Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[85]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[86]  A. Lees,et al.  Clinical features of parkinsonian patients with the α‐synuclein (G209A) mutation , 2001 .

[87]  E. Masliah,et al.  alpha-synuclein promotes mitochondrial deficit and oxidative stress. , 2000, The American journal of pathology.

[88]  D. D. Di Monte,et al.  Effects of l‐dopa and other amino acids against paraquat‐induced nigrostriatal degeneration , 2003, Journal of neurochemistry.

[89]  J. Kim.  Evidence that the precursor protein of non-A beta component of Alzheimer's disease amyloid (NACP) has an extended structure primarily composed of random-coil. , 1997, Molecules and cells.

[90]  P. Brundin,et al.  Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line* , 2002, The Journal of Biological Chemistry.

[91]  V. Uversky,et al.  Nuclear localization of alpha-synuclein and its interaction with histones. , 2003, Biochemistry.

[92]  D. Clayton,et al.  Synucleins in synaptic plasticity and neurodegenerative disorders , 1999, Journal of neuroscience research.

[93]  Y. Suh,et al.  α‐Synuclein regulates neuronal survival via Bcl‐2 family expression and PI3/Akt kinase pathway , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[94]  M. Farrer,et al.  Sensitization of Neuronal Cells to Oxidative Stress with Mutated Human α‐Synuclein , 2000 .

[95]  R. Burke,et al.  Synuclein expression is decreased in rat substantia nigra following induction of apoptosis by intrastriatal 6-hydroxydopamine , 1999, Neuroscience Letters.

[96]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[97]  H. Niznik,et al.  Direct binding and functional coupling of α‐synuclein to the dopamine transporters accelerate dopamine‐induced apoptosis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[98]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[99]  B. Giasson,et al.  Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.

[100]  Colin L. Masters,et al.  α-Synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease β-amyloid plaque cores , 1999, Neuroscience Letters.

[101]  Seung-Jae Lee,et al.  Membrane-bound α-Synuclein Has a High Aggregation Propensity and the Ability to Seed the Aggregation of the Cytosolic Form* , 2002, The Journal of Biological Chemistry.

[102]  M. Zigmond,et al.  Erratum: "A role for α-synuclein in the regulation of dopamine biosynthesis" The Journal of Neuroscience (April 15, 2002) (3090-3099)) , 2002 .

[103]  V. Uversky,et al.  The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. , 2002, The Journal of biological chemistry.

[104]  A. Matouschek,et al.  Aggregated and Monomeric α-Synuclein Bind to the S6′ Proteasomal Protein and Inhibit Proteasomal Function* , 2003, The Journal of Biological Chemistry.

[105]  H. Niznik,et al.  Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[106]  A. Sidhu,et al.  Attenuation of dopamine transporter activity by α-synuclein , 2003, Neuroscience Letters.

[107]  J. Jankovic,et al.  Polymorphism of NACP-Rep1 in Parkinson’s disease: An etiologic link with essential tremor? , 2000, Neurology.

[108]  K. Prasad,et al.  Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells , 2000, Brain Research.

[109]  J. Trojanowski,et al.  Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model , 2001 .

[110]  Takeshi Nakamura,et al.  Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. , 2002, Brain research.

[111]  Barry Halliwell,et al.  Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.

[112]  J. Penney,et al.  Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. , 2000, Annals of neurology.

[113]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[114]  V. Uversky,et al.  The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.

[115]  Smita Patel,et al.  Golgi Fragmentation Occurs in the Cells with Prefibrillar α-Synuclein Aggregates and Precedes the Formation of Fibrillar Inclusion* , 2002, The Journal of Biological Chemistry.

[116]  C. Olanow,et al.  Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures , 2002, Journal of neurochemistry.

[117]  A. Morris,et al.  Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. , 1998, Biochemistry.

[118]  B. Ghetti,et al.  Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.

[119]  S. Bunn,et al.  α-Synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells , 2003, Brain Research.

[120]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[121]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[122]  T. Chase,et al.  Degradation of α-Synuclein by Proteasome* , 1999, The Journal of Biological Chemistry.

[123]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[124]  J. Trojanowski,et al.  Neuropathology of synuclein aggregates , 2000, Journal of neuroscience research.

[125]  Rebecca A. Betensky,et al.  α-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[126]  D. Mash,et al.  Cocaine Abusers Have an Overexpression of α-Synuclein in Dopamine Neurons , 2003, The Journal of Neuroscience.

[127]  R. Burke,et al.  α‐Synuclein expression in substantia nigra and cortex in Parkinson's disease , 1999 .

[128]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[129]  P Falkai,et al.  Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. , 1999, Neuroscience letters.

[130]  D. Mash,et al.  Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[131]  H. Erdjument-Bromage,et al.  Parkinson's disease-associated alpha-synuclein is a calmodulin substrate. , 2003, The Journal of biological chemistry.

[132]  F. Checler,et al.  Wild-type but Not Parkinson's Disease-related Ala-53 → Thr Mutant α-Synuclein Protects Neuronal Cells from Apoptotic Stimuli* , 2000, The Journal of Biological Chemistry.

[133]  C. Masters,et al.  Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid. , 1999, The American journal of pathology.

[134]  B. Halliwell,et al.  Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. , 2001, Journal of neurochemistry.

[135]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[136]  J. Trojanowski,et al.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. , 2001, The American journal of pathology.

[137]  J. Trojanowski,et al.  Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * , 1999, The Journal of Biological Chemistry.

[138]  Makoto Hashimoto,et al.  Transgenic Models of α‐Synuclein Pathology , 2003 .

[139]  John Q. Trojanowski,et al.  Distinct cleavage patterns of normal and pathologic forms of α‐synuclein by calpain I in vitro , 2003 .

[140]  A. Lees,et al.  Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. , 2001, Movement disorders : official journal of the Movement Disorder Society.

[141]  A. Davies,et al.  Induction of neuronal death by α‐synuclein , 2000, The European journal of neuroscience.

[142]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[143]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[144]  E. Masliah,et al.  Alpha‐synuclein in Lewy Body Disease and Alzheimer's Disease , 1999, Brain pathology.

[145]  J. Mikkelsen,et al.  Developmental expression of α-synuclein in rat hippocampus and cerebral cortex , 1999, Neuroscience.

[146]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[147]  M. Farrer,et al.  [Genetics of Parkinson's disease]. , 2001 .

[148]  R. Perrin,et al.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. , 2000, The Journal of biological chemistry.

[149]  V. Uversky,et al.  Why are “natively unfolded” proteins unstructured under physiologic conditions? , 2000, Proteins.

[150]  C. Olanow,et al.  Proteasome inhibition causes nigral degeneration with inclusion bodies in rats , 2002, Neuroreport.

[151]  B. Hoffer,et al.  Acidic and basic fibroblast growth factor mRNAs are increased in striatum following MPTP-induced dopamine neurofiber lesion: assay by quantitative PCR. , 1993, Brain research. Molecular brain research.

[152]  E. Masliah,et al.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.

[153]  I. Kanazawa,et al.  α-Synuclein Affects the MAPK Pathway and Accelerates Cell Death* , 2001, The Journal of Biological Chemistry.

[154]  R. Krüger,et al.  Increased susceptibility to sporadic Parkinson's disease by a certain combined α‐synuclein/apolipoprotein E genotype , 1999, Annals of neurology.

[155]  A. Pastor,et al.  Regulation of connexin‐43, GFAP, and FGF‐2 is not accompanied by changes in astroglial coupling in MPTP‐lesioned, FGF‐2‐treated Parkisonian mice , 1996, Journal of neuroscience research.

[156]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[157]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[158]  Min Zhu,et al.  Lipid binding inhibits alpha-synuclein fibril formation. , 2003, The Journal of biological chemistry.

[159]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[160]  V. Uversky,et al.  Nuclear Localization of α-Synuclein and Its Interaction with Histones† , 2003 .

[161]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[162]  A. Manning-Boğ,et al.  α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration , 2003, The Journal of Neuroscience.

[163]  F. Checler,et al.  α-Synuclein and the Parkinson's disease-related mutant Ala53Thr-α-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells , 2000, Neuroscience Letters.

[164]  M. Polymeropoulos,et al.  Clinical phenotype in patients with α-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[165]  Takeshi Nakamura,et al.  Activation of Pyk2/RAFTK induces tyrosine phosphorylation of alpha-synuclein via Src-family kinases. , 2002, FEBS letters.

[166]  E. Junn,et al.  Human α-Synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine , 2002, Neuroscience Letters.

[167]  Ralf Langen,et al.  Structural Organization of α-Synuclein Fibrils Studied by Site-directed Spin Labeling* , 2003, Journal of Biological Chemistry.

[168]  G. Halliday,et al.  Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. , 2001, Annals of neurology.

[169]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[170]  Tetsuya Takahashi,et al.  Activation of Pyk2/RAFTK induces tyrosine phosphorylation of α‐synuclein via Src‐family kinases , 2002 .

[171]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[172]  J. Trojanowski,et al.  Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.

[173]  M. Spillantini,et al.  α‐Synuclein metabolism and aggregation is linked to ubiquitin‐independent degradation by the proteasome , 2001, FEBS letters.

[174]  David W. Miller,et al.  Expression of α‐synuclein, parkin, and ubiquitin carboxy‐terminal hydrolase L1 mRNA in human brain: Genes associated with familial Parkinson's disease , 2000 .

[175]  E. Masliah,et al.  NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. , 1997, Biochemical and biophysical research communications.

[176]  C. Olanow,et al.  Selective loss of 20S proteasome α-subunits in the substantia nigra pars compacta in Parkinson's disease , 2002, Neuroscience Letters.

[177]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[178]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[179]  David W. Miller,et al.  Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice , 2003, Neurobiology of Aging.

[180]  Min Zhu,et al.  Lipid Binding Inhibits α-Synuclein Fibril Formation* , 2003, The Journal of Biological Chemistry.

[181]  R. Burke,et al.  Increased Expression of Rat Synuclein in the Substantia Nigra Pars Compacta Identified by mRNA Differential Display in a Model of Developmental Target Injury , 1999, Journal of neurochemistry.

[182]  J. Mallet,et al.  Rat α‐Synuclein Interacts with Tat Binding Protein 1, a Component of the 26S Proteasomal Complex , 2000 .

[183]  J. Trojanowski,et al.  Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease , 2001, Brain Research.

[184]  J. Trojanowski,et al.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. , 2002, The Journal of biological chemistry.

[185]  Fran Maher,et al.  Non-Aβ Component of Alzheimer's Disease Amyloid (NAC) Revisited: NAC and α-Synuclein Are Not Associated with Aβ Amyloid , 1999 .

[186]  J B Schulz,et al.  Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice , 2001, Journal of neurochemistry.

[187]  Bruce A. Yankner,et al.  Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.

[188]  P. Lansbury,et al.  Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. , 2000, Biochemistry.

[189]  Hitoshi Takahashi,et al.  Immunohistochemical comparison of α- and β-synuclein in adult rat central nervous system , 2002, Brain Research.

[190]  A. Sidhu,et al.  Modulation of dopamine transporter function by α‐synuclein is altered by impairment of cell adhesion and by induction of oxidative stress , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[191]  S. Tabrizi,et al.  Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. , 2000, Human molecular genetics.

[192]  R. Scheller,et al.  The rat brain synucleins; family of proteins transiently associated with neuronal membrane. , 1991, Brain research. Molecular brain research.

[193]  R. Nussbaum,et al.  Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. , 2001, Human molecular genetics.

[194]  H. Erdjument-Bromage,et al.  Parkinson's Disease-associated α-Synuclein Is a Calmodulin Substrate* , 2003, The Journal of Biological Chemistry.

[195]  R. Burke,et al.  Synuclein‐1 is selectively up‐regulated in response to nerve growth factor treatment in PC12 cells , 2001, Journal of neurochemistry.

[196]  R. Burke,et al.  Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. , 1999, Movement disorders : official journal of the Movement Disorder Society.

[197]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[198]  R. Nussbaum,et al.  Lipid Droplet Binding and Oligomerization Properties of the Parkinson's Disease Protein α-Synuclein* , 2002, The Journal of Biological Chemistry.

[199]  J. Trojanowski,et al.  Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. , 2003, The American journal of pathology.

[200]  L. Stefanis,et al.  Proteasomal Inhibition-Induced Inclusion Formation and Death in Cortical Neurons Require Transcription and Ubiquitination , 2002, Molecular and Cellular Neuroscience.

[201]  P. Lansbury,et al.  NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.

[202]  John Q. Trojanowski,et al.  Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies , 2003 .

[203]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[204]  P. S. St George-Hyslop,et al.  Defective membrane interactions of familial Parkinson's disease mutant A30P α-synuclein , 2002 .

[205]  J. Mallet,et al.  Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. , 2000, Journal of neurochemistry.

[206]  Hitoshi Takahashi,et al.  Demonstration of α-Synuclein Immunoreactivity in Neuronal and Glial Cytoplasm in Normal Human Brain Tissue Using Proteinase K and Formic Acid Pretreatment , 2002, Experimental Neurology.

[207]  John Q. Trojanowski,et al.  Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.

[208]  L. Thal,et al.  Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. , 1998, Journal of neurochemistry.

[209]  P. Axelsen,et al.  Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .

[210]  J. Benovic,et al.  Synucleins Are a Novel Class of Substrates for G Protein-coupled Receptor Kinases* , 2000, The Journal of Biological Chemistry.

[211]  J. Trojanowski,et al.  Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. , 2000, Science.

[212]  P. Højrup,et al.  α-Synuclein Binds to Tau and Stimulates the Protein Kinase A-catalyzed Tau Phosphorylation of Serine Residues 262 and 356* , 1999, The Journal of Biological Chemistry.

[213]  Kiowa S. Bower,et al.  Accelerated α‐synuclein fibrillation in crowded milieu , 2002 .

[214]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[215]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[216]  J. Trojanowski,et al.  Prominent Perikaryal Expression of α- and β-Synuclein in Neurons of Dorsal Root Ganglion and in Medullary Neurons , 2001, Experimental Neurology.

[217]  Ronald L Klein,et al.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.

[218]  Z. Wszolek,et al.  Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. , 1999, Annals of neurology.

[219]  Tetsuya Takahashi,et al.  Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. , 2001, Biochemical and biophysical research communications.

[220]  Makoto Hashimoto,et al.  Transgenic models of alpha-synuclein pathology: past, present, and future. , 2003, Annals of the New York Academy of Sciences.

[221]  J. Feldon,et al.  Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP. , 2002, Journal of neurobiology.

[222]  J. George,et al.  The synucleins , 2001, Genome Biology.

[223]  P. Caroni,et al.  Neuropathology in mice expressing human alpha-synuclein. , 2000, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[224]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[225]  Hitoshi Takahashi,et al.  Immunohistochemical comparison of alpha- and beta-synuclein in adult rat central nervous system. , 2002, Brain research.

[226]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[227]  Kiowa S. Bower,et al.  Accelerated alpha-synuclein fibrillation in crowded milieu. , 2002, FEBS letters.

[228]  D. Dickson,et al.  Alpha-synuclein and the Lewy body disorders. , 2001, Current opinion in neurology.